American Biogenetic Sciences' Global Network is a
revolutionary concept which promotes and facilitates
collaborative scientific research within a forum which
recognizes no geographical, political or cultural
This unique ABS partnership of individual researchers at leading universities and hospitals in the U.S., Europe and China, makes an immense contribution to the biopharmaceutical industry by compromising a unique platform in which scientists from around the world can communicate and collaborate on ABS funded projects.
It has assisted in creating a strong flow of innovative technology through the ABS product pipeline most notably the promising compounds for neurological diseases, which have been tested and identified in Europe, Israel and China. In addition, it offers a first look at some of the most exciting and novel technology and drug leads outside the focus of ABS, which could be licensed to interested pharmaceutical companies.
In over 60 leading medical and scientific institutions worldwide, suitable projects have been assessed on the basis of their novel merit, patentability and timelines, all of which complement the overall research and development within ABS. When a decision to proceed is made, it is structured in a manner which serves the interest and requirements of the collaborator, his/her team and ABS. On account of this, the company utilizes the existing facilities at these sites, thereby limiting the expenditures on ABS laboratories and allowing further investment in intellectual property.